Top

European Archives of Oto-Rhino-Laryngology

Open Access 06-09-2024 | Audiometry | Head and Neck

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer

Authors: A. V. M. Burger, C. W. Duinkerken, K. E. van Sluis, J. P. de Boer, A. Navran, C. P. Lanting, K. Jóźwiak, W. A. Dreschler, A. J. M. Balm, C. L. Zuur

Published in: European Archives of Oto-Rhino-Laryngology

Abstract

Purpose

Cisplatin-induced hearing loss is a common side effect in patients treated with cisplatin-based chemoradiation (CRT) for head and neck squamous cell carcinoma. The extent of hearing loss after concurrent CRT was compared between triweekly (3 × 100 mg/m²) and weekly (7 × 40 mg/m²) cisplatin CRT.

Method

This retrospective cohort study was conducted in the Antoni van Leeuwenhoek Hospital and included 129 patients with cisplatin-based CRT for head and neck cancer (72 treated in the triweekly and 57 in the weekly regimen). Baseline and follow-up pure tone audiometry was conducted to assess hearing loss. Clinically relevant hearing loss was defined as a decline upon treatment of ≥ 10 decibel at a pure tone average 1-2-4 kHz and/or 8-10-12.5 kHz.

Results

The incidence of clinically relevant cisplatin CRT induced hearing loss was 42% in the triweekly versus 19% in the weekly group (p < 0.01). The mean threshold shift at a pure tone average (PTA) 1-2-4 kHz was 9.0 decibel in the triweekly compared to 4.3 decibel in the weekly CRT group (p < 0.01). At PTA 8-10-12.5 kHz, the incidence of clinically relevant hearing loss was 75% in the triweekly compared to 74% in the weekly CRT group (p = 0.87). The mean threshold shift at PTA 8-10-12.5 kHz was 20.2 decibel versus 15.6 decibel, respectively (p = 0.07).

Conclusion

Cisplatin-dose reduction to a weekly cisplatin CRT regimen for head and neck cancer may reduce the incidence of clinically relevant hearing loss at frequencies vital for speech perception.

Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of rtog 91 – 11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852. https://doi.org/10.1200/JCO.2012.43.6097CrossRefPubMed

Bauml JM, Vinnakota R, Anna Park YH et al (2019) Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. J Natl Cancer Inst 111(5):490–497. https://doi.org/10.1093/jnci/djy133CrossRefPubMed

Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. https://doi.org/10.1056/NEJMoa032641CrossRefPubMed

Paken J, Govender CD, Pillay M, Sewram V (2016) Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol 2016:1809394. https://doi.org/10.1155/2016/1809394CrossRefPubMedPubMedCentral

Callejo A, Sedo-Cabezon L, Juan ID, Llorens J (2015) Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics 3(3):268–293. https://doi.org/10.3390/toxics3030268CrossRefPubMedPubMedCentral

Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226(1–2):157–167. https://doi.org/10.1016/j.heares.2006.09.015CrossRefPubMed

Karasawa T, Steyger PS (2015) An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 237(3):219–227. https://doi.org/10.1016/j.toxlet.2015.06.012CrossRefPubMedPubMedCentral

Lanvers-Kaminsky C, Zehnhoff-Dinnesen AA, Parfitt R, Ciarimboli G (2017) Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies. Clin Pharmacol Ther 101(4):491–500. https://doi.org/10.1002/cpt.603CrossRefPubMed

Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R (2003) Radiotherapy-induced ear toxicity. Cancer Treat Rev 29:417–430CrossRefPubMed

10.

Schmitt NC, Page BR (2018) Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Int J Audiol 57(sup4):S49–S54. https://doi.org/10.1080/14992027.2017.1353710CrossRefPubMed

11.

Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM (2022) Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol 79:102203. https://doi.org/10.1016/j.canep.2022.102203CrossRefPubMedPubMedCentral

12.

Theunissen EA, Bosma SC, Zuur CL et al (2015) Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck 37(2):281–292. https://doi.org/10.1002/hed.23551CrossRefPubMed

13.

Rybak LP, Mukherjea D, Ramkumar V (2019) Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear 40(2):197–204. https://doi.org/10.1055/s-0039-1684048CrossRefPubMedPubMedCentral

14.

Zuur CL, Simis YJ, Lansdaal PE et al (2006) Audiometric patterns in ototoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurootol 11(5):318–330. https://doi.org/10.1159/000095818CrossRefPubMed

15.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 35:2712–2720CrossRef

16.

Trendowski MR, El Charif O, Dinh PC Jr., Travis LB, Dolan ME (2018) Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. doi: 10.1158/1078 – 0432.CCR-18-2244

17.

Spreafico A, Huang SH, Xu W et al (2016) Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 67:174–182. https://doi.org/10.1016/j.ejca.2016.08.013CrossRefPubMed

18.

Strojan P, Vermorken JB, Beitler JJ et al (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 38(Suppl 1):E2151–E2158. https://doi.org/10.1002/hed.24026CrossRefPubMed

19.

Wendrich AW, Swartz JE, Bril SI et al (2017) Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol 71:26–33. https://doi.org/10.1016/j.oraloncology.2017.05.012CrossRefPubMed

20.

Bril SI, Al-Mamgani A, Chargi N et al (2021) The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head Neck 44(1):189–200. https://doi.org/10.1002/hed.26919CrossRefPubMedPubMedCentral

21.

Beijer YJ, Koopman M, Terhaard CH, Braunius WW, van Es RJ, de Graeff A (2013) Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients. Clin Otolaryngol 38(1):69–74. https://doi.org/10.1111/coa.12002CrossRefPubMed

22.

Helfenstein S, Riesterer O, Meier UR et al (2019) 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. Radiat Oncol 14(1):32. https://doi.org/10.1186/s13014-019-1235-yCrossRefPubMedPubMedCentral

23.

Zuur CL, Simis YJ, Lansdaal PE et al (2007) Ototoxicity in a randomized phase iii trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25(24):3759–3765. https://doi.org/10.1200/JCO.2006.08.9540CrossRefPubMed

24.

Landier W (2016) Ototoxicity and cancer therapy. Cancer 122(11):1647–1658. https://doi.org/10.1002/cncr.29779CrossRefPubMed

25.

Bhandare N, Jackson A, Eisbruch A et al (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3 Suppl):S50–S57. https://doi.org/10.1016/j.ijrobp.2009.04.096CrossRefPubMedPubMedCentral

26.

Iso (1998) 389-1, acoustics - reference zero for the calibration of audiometric equipment

27.

Motlagh Zadeh L, Silbert NH, Sternasty K, Swanepoel W, Hunter LL, Moore DR (2019) Extended high-frequency hearing enhances speech perception in noise. Proc Natl Acad Sci U S A 116(47):23753–23759. https://doi.org/10.1073/pnas.1903315116CrossRefPubMedPubMedCentral

28.

Polspoel S, Kramer SE, van Dijk B, Smits C (2022) The importance of extended high-frequency speech information in the recognition of digits, words, and sentences in quiet and noise. Ear Hear 43(3):913–920. https://doi.org/10.1097/aud.0000000000001142CrossRefPubMed

29.

American speech-language-hearing association (asha), guidelines: Audiologic management of individuals receiving cochleotoxic drug therapy. https://wwwashaorg/policy/gl1994-00003/#sec214.

30.

U.S. Department of health and human services: Common terminology criteria for adverse events (ctcae) version 5.0 (2017) https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf

31.

Theunissen EA (2014) A new grading system for ototoxicity in adults. https://doi.org/10.1177/0003489414534010

32.

Chattaraj A, Syed MP, Low CA, Owonikoko TK (2023) Cisplatin-induced ototoxicity: a concise review of the burden, prevention, and interception strategies. JCO Oncol Pract 19(5):278–283. https://doi.org/10.1200/OP.22.00710CrossRefPubMedPubMedCentral

33.

Noronha V, Joshi A, Patil VM et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase iii randomized noninferiority trial. J Clin Oncol 36(11):1064–1072. https://doi.org/10.1200/JCO.2017.74.9457CrossRefPubMed

34.

Deal JA, Reed NS, Kravetz AD et al (2019) Incident hearing loss and comorbidity, a longitudinal administrative claims study. JAMA Otolaryngol Head Neck Surg 145:36–43. https://doi.org/10.1001/jamaoto.2018.2876CrossRefPubMed

35.

Apoorva KV, Vijendra Shenoy S, Athiyamaan MS, Kabekkodu S, Kshithi K, Zuturu N (2023) Radiation dose to the cochlea and its association with sensorineural hearing loss in head and neck cancer-a prospective study. Am J Otolaryngol 44(4):103914. https://doi.org/10.1016/j.amjoto.2023.103914CrossRefPubMed

36.

Laurell G (2019) Pharmacological intervention in the field of ototoxicity. HNO 67(6):434–439. https://doi.org/10.1007/s00106-019-0663-1CrossRefPubMedPubMedCentral

37.

Guthrie OW, Spankovich C (2023) Emerging and established therapies for chemotherapy-induced ototoxicity. J Cancer Surviv. https://doi.org/10.1007/s11764-022-01317-6CrossRefPubMed

38.

Duinkerken CW, de Weger VA, Dreschler WA et al (2021) Transtympanic sodium thiosulfate for prevention of cisplatin-induced ototoxicity: a randomized clinical trial. Otol Neurotol 42(5):678–685. https://doi.org/10.1097/MAO.0000000000003069CrossRefPubMed

Title: Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer
Authors: A. V. M. Burger
C. W. Duinkerken
K. E. van Sluis
J. P. de Boer
A. Navran
C. P. Lanting
K. Jóźwiak
W. A. Dreschler
A. J. M. Balm
C. L. Zuur
Publication date: 06-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: Audiometry
Audiometry
Published in: European Archives of Oto-Rhino-Laryngology
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-024-08880-x

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer

Abstract

Purpose

Method

Results

Conclusion

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose

Method

Results

Conclusion

Please log in to get access to this content